2-(2,3-dicarboxycyclopropyl)glycine has been researched along with bucladesine in 1 studies
Studies (2-(2,3-dicarboxycyclopropyl)glycine) | Trials (2-(2,3-dicarboxycyclopropyl)glycine) | Recent Studies (post-2010) (2-(2,3-dicarboxycyclopropyl)glycine) | Studies (bucladesine) | Trials (bucladesine) | Recent Studies (post-2010) (bucladesine) |
---|---|---|---|---|---|
166 | 0 | 27 | 9,775 | 13 | 210 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Buisson, A; Choi, DW; Yu, SP | 1 |
1 other study(ies) available for 2-(2,3-dicarboxycyclopropyl)glycine and bucladesine
Article | Year |
---|---|
DCG-IV selectively attenuates rapidly triggered NMDA-induced neurotoxicity in cortical neurons.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Bucladesine; Cell Death; Cell Survival; Cells, Cultured; Cerebral Cortex; Cyclic AMP; Cyclopropanes; Glycine; Kainic Acid; Membrane Potentials; Mice; N-Methylaspartate; Neurons; Neurotoxins; Pertussis Toxin; Receptors, Metabotropic Glutamate; Virulence Factors, Bordetella | 1996 |